Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP419997.RAaCuEJOCLL30lslppSKj-eUISWADM57B_LjLRCH4Smok130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP419997.RAaCuEJOCLL30lslppSKj-eUISWADM57B_LjLRCH4Smok130_assertion type Assertion NP419997.RAaCuEJOCLL30lslppSKj-eUISWADM57B_LjLRCH4Smok130_head.
- NP419997.RAaCuEJOCLL30lslppSKj-eUISWADM57B_LjLRCH4Smok130_assertion description "[In contrast, administration of the selective progesterone receptor antagonist reduced overexpression of Pmp22 and improved the CMT phenotype, without obvious side effects, in wild-type or transgenic rats.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP419997.RAaCuEJOCLL30lslppSKj-eUISWADM57B_LjLRCH4Smok130_provenance.
- NP419997.RAaCuEJOCLL30lslppSKj-eUISWADM57B_LjLRCH4Smok130_assertion evidence source_evidence_literature NP419997.RAaCuEJOCLL30lslppSKj-eUISWADM57B_LjLRCH4Smok130_provenance.
- NP419997.RAaCuEJOCLL30lslppSKj-eUISWADM57B_LjLRCH4Smok130_assertion SIO_000772 14608378 NP419997.RAaCuEJOCLL30lslppSKj-eUISWADM57B_LjLRCH4Smok130_provenance.
- NP419997.RAaCuEJOCLL30lslppSKj-eUISWADM57B_LjLRCH4Smok130_assertion wasDerivedFrom befree-2016 NP419997.RAaCuEJOCLL30lslppSKj-eUISWADM57B_LjLRCH4Smok130_provenance.
- NP419997.RAaCuEJOCLL30lslppSKj-eUISWADM57B_LjLRCH4Smok130_assertion wasGeneratedBy ECO_0000203 NP419997.RAaCuEJOCLL30lslppSKj-eUISWADM57B_LjLRCH4Smok130_provenance.